Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 4/20 | 0.44 |
| ▸ | ACHE known ✓ | P22303 | 9/20 | 0.42 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321885 | 0.98 | CHRNA7 (0.48) | CHRNA7CHRM3ACHECHRM2CHRNB2 | |
| Iodide SCHEMBL195619 | 0.96 | CHRNA7 (0.47) | CHRNA7CHRM3ACHECHRM2CHRNB2 | |
| SCHEMBL8346963 | 0.90 | CHRNA7 (0.43) | CHRNA7CHRM3ACHECHRM2CHRNB2 | |
| SCHEMBL4258543 | 0.89 | CHRNA7 (0.42) | CHRNA7CHRM3ACHECHRM2CHRNB2 | |
| SCHEMBL10256548 | 0.87 | CHRNA7 (0.52) | CHRNA7CHRM3ACHECHRM2CHRNB2 | |
| Hydrochloric Acid SCHEMBL11194479 | 0.86 | CHRNA7 (0.47) | CHRNA7CHRM3ACHECHRNB2CHRNA4 | |
| SCHEMBL4256635 | 0.85 | CHRNA7 (0.45) | CHRNA7CHRM3ACHECHRM2 | |
| Trifluoromethanesulfonic Acid SCHEMBL8349313 | 0.83 | CHRNA7 (0.39) | CHRNA7CHRM3ACHECHRM2 | |
| SCHEMBL10257199 | 0.80 | KCNH2 (0.48) | CHRNA7CHRM3CHRM2 | |
| Bromide SCHEMBL2450495 | 0.79 | CHRNB2 (0.59) | CHRNA7CHRM3CHRM2CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081543-A2 | BLEACHING AGENT COMPRISING PIPERIDONE/S AND IMIDAZOLE/S | Henkel AG & Co. KGaA (DE) | 2009-07-29 | — | — | EP | claimed |
| WO-2008095558-A2 | BLEACHING AGENT COMPRISING PIPERIDONE/S AND IMIDAZOLE/S | HENKEL AG & CO. KGAA (DE) | 2008-08-14 | — | — | WO | claimed |
| CN-106795117-B | Heterobicyclic compounds and their use for the treatment of tuberculosis | 大塚制药株式会社 | 2020-06-26 | — | — | CN | disclosed |
| US-10464926-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-11-05 | — | — | US | disclosed |
| EP-3186240-B1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2019-06-12 | — | — | EP | disclosed |
| US-20180312488-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-11-01 | — | — | US | disclosed |
| US-10053446-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-08-21 | — | — | US | disclosed |
| US-20170253576-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| EP-3186240-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016031255-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-03-03 | — | — | WO | disclosed |
| US-20130045993-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES AND THEIR USE | Piramal Enterprises Limited (IN) | 2013-02-21 | — | — | US | disclosed |
| US-20080108690-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASES AND THEIR USE | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2008-05-08 | — | — | US | disclosed |
| US-7271193-B2 | Inhibitors of cyclin-dependent kinases and their use | NICHOLAS PIRAMAL INDIA, LTD. (IN) | 2007-09-18 | — | — | US | disclosed |
| US-20070043065-A1 | Amide derivatives | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| US-20070015802-A1 | chromenone derivatives of nitrogen-, oxygen- or sulfur-containing saturated heterocycles; preparation by cyclizing benzoyl intermediates; antiproliferative agents; 2-(2-Chloro-phenyl)-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-5,7-dimethoxy-chromen-4-one; acidification | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-18 | — | — | US | disclosed |
| EP-1682520-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2006-07-26 | — | — | EP | disclosed |
| EP-1556375-A2 | FLAVONE DERIVATIVES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | Nicholas Piramal India Limited (IN) | 2005-07-27 | — | — | EP | disclosed |
| WO-2005042502-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-05-12 | — | — | WO | disclosed |
| US-20040106581-A1 | Inhibitors of cyclin-dependent kinases and their use | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2004-06-03 | — | — | US | disclosed |
| WO-2004004632-A2 | FLAVONE DERIVATIVES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106581-A1 | Inhibitors of cyclin-dependent kinases and their use | CCNK, CCNI, CDK1 | CHRM3 3228/4885ACHE 3814/4885CHRM2 3296/4885 |
| US-10053446-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | FNTB, SLC11A2, TBCD | CHRM3 2568/4885ACHE 1159/4885CHRM2 1483/4885 |
| US-20070043065-A1 | Amide derivatives | IL6, IL2, IL1B | CHRM3 643/4885ACHE 3152/4885CHRM2 262/4885 |
| US-20080108690-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASES AND THEIR USE | CDK1, CCNK, CCNI | CHRM3 1328/4885ACHE 2283/4885CHRM2 1078/4885 |
| US-10464926-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | FNTB, SLC11A2, TBCD | CHRM3 2568/4885ACHE 1159/4885CHRM2 1483/4885 |
| US-20180312488-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | FNTB, SLC11A2, TBCD | CHRM3 2568/4885ACHE 1159/4885CHRM2 1483/4885 |
| US-20170253576-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | FNTB, SLC11A2, TBCD | CHRM3 2568/4885ACHE 1159/4885CHRM2 1483/4885 |
| US-20130045993-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES AND THEIR USE | CDK1, CCNK, CCNI | CHRM3 1519/4885ACHE 2646/4885CHRM2 1251/4885 |
| US-20070015802-A1 | chromenone derivatives of nitrogen-, oxygen- or sulfur-containing saturated heterocycles; preparation by cyclizing benzoyl intermediates; antiproliferative agents; 2-(2-Chloro-phenyl)-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-5,7-dimethoxy-chromen-4-one; acidification | CCNI, CDK1, CCNA1 | CHRM3 1406/4885ACHE 3942/4885CHRM2 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.